Form 4: Keros Therapeutics Director Carl L. Gordon Reports Stock Sales
SEC Form 4 Filing
Director Carl L. Gordon reported the sale of Keros Therapeutics (KROS) stock held indirectly through OrbiMed funds on August 13, 2024.
Summary
- Carl L. Gordon, a director of Keros Therapeutics, reported the sale of shares held indirectly through OrbiMed Private Investments VII, LP and OrbiMed Genesis Master Fund, L.P.
- On August 13, 2024, 220,600 shares were sold at a price of $44.01.
- On the same day, another 29,400 shares were sold at the same price of $44.01.
- Following these transactions, the number of shares beneficially owned indirectly through OrbiMed Private Investments VII, LP is 899,212.
- The number of shares beneficially owned indirectly through OrbiMed Genesis Master Fund, L.P. is 119,522.
- Gordon disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting stock sales by a director, which is neutral in sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders of a company (such as directors or officers) buy or sell the company's securities; this provides transparency to the market.
Key Dates
| Date | Description |
|---|---|
| 08/13/2024 | Date of stock sale transactions |
| 08/15/2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.